scholarly journals Implementation and Rationale for a Unified Clinical and Imaging Protocol for Evaluation and Treatment of Moyamoya Angiopathy: A Single Institutional Experience

2021 ◽  
Vol 12 ◽  
Author(s):  
Anthony S. Larson ◽  
Vance T. Lehman ◽  
Luis E. Savastano ◽  
Giuseppe Lanzino ◽  
Norbert G. Campeau ◽  
...  

Moyamoya disease (MMD) is a complex and incompletely-understood cerebrovascular pathological entity that requires thorough clinical and imaging evaluation. Moyamoya is rare, thereby making the establishment of an effective, thorough and interdisciplinary patient evaluation protocol challenging, even within specialized referral centers. Nevertheless, implementation of such a protocol is crucial in order to provide the best possible evaluation and treatment for MMD patients. Here, we describe our institution's implementation of, rationale for, and experience with a comprehensive multidisciplinary collaboration and evaluation strategy for adult patients with moyamoya. This evaluation course consists of, first of all, a thorough clinical and laboratory evaluation with a vascular neurologist. This is followed by a comprehensive imaging assessment which evaluates angiographic and parenchymal features, in addition to cerebrovascular functionality. Finally, appropriate referrals are made to consulting services as indicated, which includes vascular neurosurgery. These steps are described in detail herein.

2014 ◽  
Vol 01 (02) ◽  
pp. 131-136 ◽  
Author(s):  
Vivek Sharma ◽  
Hemanshu Prabhakar ◽  
Girija Rath ◽  
Parmod Bithal

Abstract Background: Moyamoya disease (MMD) is a chronic cerebrovascular disorder, defined as the progressive stenosis or occlusion of the intracranial vessels. Because of the insecure cerebral circulation, these patients represent an anaesthetic challenge. Literature is scarce on the anaesthetic management of MMD, especially from the Indian subcontinent. The main objective of our study was to evaluate the peri-operative course and outcome of patients undergoing surgery for MMD. Materials and Methods: We analysed available medical records of all patients who underwent revascularisation surgeries for MMD over a period of 10 years (January 2002 to June 2012). Various intra- and post-operative data related to anaesthesia were recorded. The patients for the analysis were divided into two groups: Group 1, paediatrics (<18 years) and group 2, adults (≥18 years). Data are presented as number (%) or mean ± SD or median (range). Results: There were 36 patients (12 adults and 24 children). Normotension, normovolaemia, normo- or mild-hypercapnia and normothermia were maintained in all patients. No patient developed complications or new neurological deficit in the post-operative period. All patients were discharged with a full Glasgow coma scale (GCS) and no new neurologic deficit. Conclusion: Although the incidence of MMD is not high in India, it is an important cause of cerebral stroke in children and adults. Proper pre-operative evaluation is the most effective method to achieve good results. Anaesthetic management of MMD should focus on the maintenance of adequate cerebral blood flow and cerebral perfusion pressure ensuring adequate cerebral oxygenation to avoid ischaemic complications.


Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6020
Author(s):  
Francesca Maria Orlandella ◽  
Luigi Auletta ◽  
Adelaide Greco ◽  
Antonella Zannetti ◽  
Giuliana Salvatore

Background: We have conducted a systematic review focusing on the advancements in preclinical molecular imaging to study the delivery and therapeutic efficacy of miRNAs in mouse models of breast cancer. Methods: A systematic review of English articles published in peer-reviewed journals using PubMed, EMBASE, BIOSIS™ and Scopus was performed. Search terms included breast cancer, mouse, mice, microRNA(s) and miRNA(s). Results: From a total of 2073 records, our final data extraction was from 114 manuscripts. The most frequently used murine genetic background was Balb/C (46.7%). The most frequently used model was the IV metastatic model (46.8%), which was obtained via intravenous injection (68.9%) in the tail vein. Bioluminescence was the most used frequently used tool (64%), and was used as a surrogate for tumor growth for efficacy treatment or for the evaluation of tumorigenicity in miRNA-transfected cells (29.9%); for tracking, evaluation of engraftment and for response to therapy in metastatic models (50.6%). Conclusions: This review provides a systematic and focused analysis of all the information available and related to the imaging protocols with which to test miRNA therapy in an in vivo mice model of breast cancer, and has the purpose of providing an important tool to suggest the best preclinical imaging protocol based on available evidence.


Author(s):  
Bharat Sharma ◽  
Shashi Sharma ◽  
Naveen Bhardwaj ◽  
Sakshi Dewan ◽  
Mir Aziz ◽  
...  

2011 ◽  
Vol 59 (5) ◽  
pp. 733 ◽  
Author(s):  
HimaShriniwas Pendharkar ◽  
Narendra Bodhey ◽  
SwatiDayanand Chinchure ◽  
ArunKumar Gupta ◽  
KJ Harsha

2008 ◽  
Vol 66 (3a) ◽  
pp. 449-453 ◽  
Author(s):  
Fernanda Rueda ◽  
Luiz Celso Hygino Jr ◽  
Romeu Cortês Domingues ◽  
Cláudia C. Vasconcelos ◽  
Regina M. Papais-Alvarenga ◽  
...  

OBJECTIVE: To evaluate the fractional anisotropy (FA) values of the normal-appearing white matter of the corpus callosum (CC) in patients with relapsing-remitting multiple sclerosis (MS). METHOD: Fifty-seven patients with diagnosis of relapsing-remitting MS and 47 age- and gender-matched controls were studied. A conventional MR imaging protocol and a DTI sequence were performed. One neuroradiologist placed the regions of interest (ROIs) in the FA maps in five different portions of the normal-apearing CC (rostrum, genu, anterior and posterior portion of the body and splenium) in all cases. The statistical analysis was performed with the Mann-Whitney U test and p<0.05 was considered statistically significant. RESULTS: The FA values were lower in the MS patients compared with the controls (p<0.05) in the following CC regions: rostrum (0.720 vs 0.819), anterior body (0.698 vs 0.752), posterior body (0.711 vs 0.759) and splenium (0.720 vs 0.880). CONCLUSION: In this series, there was a robust decrease in the FA in all regions of the normal-appearing CC, being significant in the rostrum, body and splenium. This finding suggests that there is a subtle and diffuse abnormality in the CC, which could be probably related to myelin content loss, axonal damage and gliosis.


2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A690-A690
Author(s):  
Marianne Jacob ◽  
Dix Poppas ◽  
Oksana Lekarev

Abstract Background: Precocious puberty in girls is defined as onset of secondary sexual characteristics, such as breast development, before 8 years of age. To differentiate between central and peripheral precocious puberty, laboratory and imaging evaluation is helpful. When gonadotropins are low but estradiol is elevated, results may suggest a primary ovarian source of estrogen production. Small ovarian cysts are not uncommon, are benign and self-resolve. However, large ovarian cysts are rare, let alone ones requiring surgical removal. Clinical Case: A 6 year 7 month old girl presented with several days of breast tenderness and palpable bilateral breast tissue noted by her mother. There was no history of vaginal bleeding. There were no reported exposures to estrogen-containing products. Her mother reached menarche at age 14 years. The patient was born full term and was otherwise healthy. On exam, her height was at the 90-95th %ile (mid-parental height at the 95th %ile) and her growth velocity was 10.9 cm/yr. She had Tanner 2 breasts (1 cm breast bud on the left and 1.5 cm on the right), Tanner 1 pubic hair and no axillary hair, body odor, acne or café-au-lait macules. A bone age was read as 6 years at a chronological age of 6 years 7 months. A laboratory evaluation revealed an estradiol of 1,029 pg/mL (&lt;15 pg/mL), LH &lt;0.02 mIU/mL, FSH &lt;0.09 mIU/mL, 17-hydroxyprogesterone (17-OHP) 410 ng/dL (&lt;91 ng/dL), AFP 2.3 ng/mL (&lt;6.1 ng/mL), beta-hCG &lt;2 mIU/mL, TSH 2.41 mIU/L (0.5-3.2 mIU/L), and free T4 0.9 ng/dL (0.9-1.4 ng/dL). Pelvic ultrasound revealed a large unilocular cystic structure measuring 6.5 x 4.1 x 6.1 cm in the left adnexal region with no left ovary visualized. The right ovary appeared prepubertal. The uterus was prepubertal in appearance with endometrial thickness of 2 mm. Abdominal ultrasound showed no evidence of a suprarenal mass. A laparoscopic cyst resection was completed, given the risk of left ovarian torsion. Cytology was negative; pathology revealed a luteinized follicular cyst. Repeat labs in one month showed a prepubertal estradiol level of 6.7 pg/mL with LH 0.02 mIU/mL and FSH 0.38 mIU/mL. 17-OHP normalized to 29 ng/dL. Breast tissue had regressed. Conclusion: This case describes the rare finding of a large luteinized follicular ovarian cyst that required surgical removal in a 6-year-old girl in the setting of a significantly elevated estradiol level. Luteinized follicular cysts have been described in newborns, though rare. To our knowledge, this is the first described case of a luteinized follicular cyst in this patient’s age group. Laboratory and imaging evaluation should be considered in girls presenting with precocious puberty, despite the extent of thelarche, as the clinical examination does not always correlate with degree of estradiol elevation. This is especially important if clinical changes are acute and other features are consistent with puberty, such as rapid linear growth.


2021 ◽  
Author(s):  
Francesca Maria Orlandella ◽  
Luigi Auletta ◽  
Adelaide Greco ◽  
Antonella Zannetti ◽  
Giuliana Salvatore

Abstract Background: miRNAs have been defined as a tumor suppressor or oncogene (oncomiR) in several human cancers. We have conducted a systematic review highlighting and specifically focusing in the advancements in preclinical molecular imaging to study in vivo the delivery and the therapeutic efficacy of miRNAs in mouse models of breast cancer.Methods: A systematic review of English articles published in peer-reviewed journals using PubMed® (including MEDLINE®), EMBASE, BIOSIS™, Scopus was performed. Search terms included breast cancer, mouse, mice, microRNA(s) and miRNA(s). The search was focused on the last five years (2015-2021). All studies using miRNA in breast cancer models which included a preclinical imaging evaluation, both in vivo or ex vivo were analyzed. Result: From a total of 2,073 records, 1,221 papers were assessed for full text eligibility, but excluding all those in which there was no use of mouse models of breast cancer, there was not in vivo imaging or ex vivo on whole organs, and without a clear link to a miRNA, our final data extraction was made on a total of 114 manuscripts. The murine genetic background most used in miRNA studies have been resulted to be the Balb/C (46,7%). Regarding cell lines, MDA-MB-231 parental and derived cells were used in most experiments (62,5%). The most used model was the i.v. metastatic model (46,8%), which was obtained via intravenous injection (68,9%) in the tail vein. The modulation of miRNA was obtained mainly by stable transfection with specific lentiviral plasmid or DNA constructs in luciferase- labelled BC cells (54,4%). Bioluminescence resulted the most used tool (64%) and was used as a surrogate of tumor growth for efficacy treatment or for the evaluation of tumorigenicity in miRNA transfected cells (29,9%); for tracking, evaluation of engraftment and for response to therapy in metastatic models (50,6%).Conclusion: this review provides a systematic and focused analysis of all the information currently available and related to the imaging protocols to test miRNA therapy in in vivo mice model of BC and has the purpose to provide an important tool to suggest the best pre-clinical imaging protocol on currently available evidences.


Author(s):  
Ephraim W Church ◽  
Teresa E Bell-Stephens ◽  
Mark G Bigder ◽  
Santosh Gummidipundi ◽  
Summer S Han ◽  
...  

Abstract BACKGROUND The natural history of unilateral moyamoya disease (MMD) progressing to bilateral MMD remains an enigma in modern vascular neurosurgery. Few, small series with limited follow-up have reported relatively high rates of contralateral stenosis progression. OBJECTIVE To review our large series of unilateral MMD patients and evaluate radiographic and surgical progression rates, and identify any factors associated with progression. METHODS We included all unilateral MMD cases treated from 1991 to 2017 in an observational study. We examined time to contralateral radiographic progression and contralateral progression requiring surgery. Using Cox regression analysis, we evaluated factors potentially associated with contralateral progression. RESULTS There were 217 patients treated for unilateral MMD. About 71% were female, and the average age at first surgery was 33.8 yr. Average follow-up was 5.8 yr (range 1-22 yr). A total of 18 patients (8.3%) developed contralateral progression. And 8 of these (3.7%) developed progression requiring bypass surgery. Baseline stenosis and hyperlipidemia (HLD) were significantly associated with radiographic progression (hazard ratio [HR] = 9.7, P = .006; HR = 4.0, P = .024). Baseline stenosis was associated with surgical progression (HR = 44.2, P = .002). Results were similar when controlling for possible confounders using multivariate regression. CONCLUSION Previous series showed relatively high rates of progression in unilateral MMD (15%-30%), but these studies were small and long-term follow-up was rarely available. Our large series indicates that the rate of progression is lower than previously reported but still warrants yearly noninvasive screening. These data may provide indirect support for statin therapy in MMD.


1976 ◽  
Vol 22 (4) ◽  
pp. 434-438 ◽  
Author(s):  
E Hardin ◽  
R B Passey ◽  
R L Gillum ◽  
J B Fuller ◽  
D Lawrence

Abstract We evaluated the Perkin-Elmer KA-150 Enzyme Analyzer in a clinical laboratory situation according to a rigid evaluation protocol. The factors evaluated for five commonly assayed enzymes were as follows: (a) rate of analysis of patient samples, (b) analytical linearity, (c) overall precision (within-run and between-day), (d) carry-over from a sample with activity near 1000 U/liter, (e) error detection at low and high concentrations, (f) correlation of values with those obtained by methods used in our laboratory and (g) normal-value ranges. We find the KA-150 to be an effective and rapid enzyme analyzer.


Sign in / Sign up

Export Citation Format

Share Document